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The Caenorhabditis elegans F-box protein SEL-10 and its human
homolog have been proposed to regulate LIN-12 Notch signaling
by targeting for ubiquitin-mediated proteasomal degradation
LIN-12 Notch proteins and SEL-12 PS1 presenilins, the latter of
which have been implicated in Alzheimer’s disease. We found that
sel-10 is the same gene as egl-41, which previously had been
defined by gain-of-function mutations that semidominantly cause
masculinization of the hermaphrodite soma. Our results demon-
strate that mutations causing loss-of-function of sel-10 also have
masculinizing activity, indicating that sel-10 functions to promote
female development. Genetically, sel-10 acts upstream of the
genes fem-1, fem-2, and fem-3 and downstream of her-1 and
probably tra-2. When expressed in mammalian cells, SEL-10 protein
coimmunoprecipitates with FEM-1, FEM-2, and FEM-3, which are
required for masculinization, and FEM-1 and FEM-3 are targeted by
SEL-10 for proteasomal degradation. We propose that SEL-10-
mediated proteolysis of FEM-1 and FEM-3 is required for normal
hermaphrodite development.
Caenorhabditis elegans develops either as a self-fertilizing XXhermaphrodite or as an X0 male (1). The X-to-autosome
(XA) ratio provides the primary sex-determining signal and
specifies the activity of her (hermaphrodization)-1. Downstream
of her-1, five genes [tra (transformer)-2, tra-3, fem ( feminiza-
tion)-1, fem-2, and fem-3] control the activity of tra-1, the
terminal, global regulator of somatic sexual fate. In XX animals,
the her-1 gene, which encodes a secreted protein, is not expressed
(2). The lack of her-1 expression in XX animals permits the
activation of the transmembrane protein TRA-2, which blocks
the functions of FEM-1 (a novel protein) (3), FEM-2 (a type 2C
protein phosphatase) (4, 5), and FEM-3 (an ankyrin-repeat
protein) (6), possibly by interacting directly with FEM-3 (7). This
block leads to the activation of the Zn-finger DNA-binding
protein TRA-1 (8). Active TRA-1 represses the transcription of
genes required for male development, resulting in the formation
of an animal with a female soma: a hermaphrodite (9, 10). In X0
animals, the HER-1 protein is present and inhibits TRA-2 (11,
12). The FEM proteins are, thus, relieved from negative regu-
lation by TRA-2, resulting in the FEM-dependent inhibition of
TRA-1 and subsequent male development.
The gene egl (egg-laying-defective)-41 was defined by three
semidominantly acting mutations, n1069, n1074, and n1077,
which were identified in a screen for egg-laying-defective (Egl)
hermaphrodites (13). Additional egl-41 alleles were identified in
screens for mutations that suppress a semidominantly acting
tra-2 mutation (e2055) (14), which cause the male-specific
cephalic companion neurons (CEMs) to survive in hermaphro-
dites (n3717; H.T.S. and H.R.H., unpublished data) or that cause
abnormalities in the sex-specific pattern of cell deaths in the
ventral cord (n3854, n4041, and n4046; B. Galvin and H.R.H.,
unpublished results). egl-41 hermaphrodites are weakly mascu-
linized; for example, in egl-41 hermaphrodites, the hermaphro-
dite-specific neurons (HSNs) die (the HSNs normally die by
programmed cell death in males and survive in hermaphrodites,
in which they are required for egg laying) and the CEM neurons,
which normally die in hermaphrodites, survive (13). All char-
acterized egl-41 alleles cause a semidominant phenotype. Semi-
dominant phenotypes often are consequences of gain-of-
function (gf) mutations that cause altered gene function. For this
reason, previous studies could not establish whether egl-41
normally acts in the sex-determination pathway. In this article,
we describe the molecular characterization of the egl-41 gene and
the phenotype caused by the loss of egl-41 function. Our results
indicate that egl-41 is the same gene as the previously charac-
terized gene sel (suppressorenhancer of lin-12)-10 and that
sel-10 normally functions in sex determination.
Materials and Methods
General Methods and Strains. C. elegans strains were maintained
at 20°C, unless otherwise noted. The strain N2 (Bristol) was the
standard wild-type strain. For single-nucleotide polymorphism
(SNP) mapping, the wild-type Hawaiian strain CB4856 was
also used. The alleles, deficiencies, and duplications that were
used in this study are as follows and are described by Riddle
et al. (15), except where noted otherwise: LGI, him-1(e879),
nIs133(pkd-2::gfp) (ref. 16 and H.T.S. and H.R.H, unpublished
data); LGII, tra-2(e1875, e2019, e2021, e2531, and n1106);
LGIII, fem-2(b245 and e2105) and lin-12(n302, n676, and
n930); LGIV, fem-1(hc17 and e1965), fem-3(e2006 and e1996),
him-8(e1489), and ced-3(n717); LGV, dpy-11(e224), her-
1(e1561, n695, and hv1 y101), unc-42(e270), lon-3(e2175),
rol-4(sc8), sel-10(ar41, n1069, n1074, n1077, and e2055), sel-
10(bc189 n1077, bc243, and n4273) (this study), sel-10(n3717)
(H.T.S. and H.R.H., unpublished data), sel-10(n3854, n4041,
and n4046) (B. Galvin and H.R.H. unpublished data), him-
5(e1490), unc-76(e911), and dpy-21(e428); and LGX, sel-
12(ar131) and sdc-1(n485). nDf42 is a deficiency spanning the
sel-10 locus (17). ctDp8(V;f ) is a free duplication spanning the
sel-10 locus (18).
Mapping of egl-41sel-10. sel-10 gf alleles have been mapped
between sqt-3 and him-5 on LGV (13). The location of n3717gf
was refined by using SNP mapping and the following SNPs:
pkP5069, pkP5070, pkP5086, pkP5088, F55B12 9,811, and
R10D12 16,645 (19). To obtain recombinants for LGV between
N2 and CB4856, the strains nIs133; rol-4(sc8) sel-10(n3717)
unc-76(e911) or rol-4(sc8) sel-10(n1077gf) unc-76(e911) were
Abbreviations: Egl, egg-laying-defective; CEM, cephalic companion neuron; HSN, her-
maphrodite-specific neuron; gf, gain-of-function; SNP, single-nucleotide polymorphism; lf,
loss-of-function; shRNA, short-hairpin RNA; hsel-10, human sel-10; SCF, Skp1–Cullin–F-box;
SEL-10Myc, Myc-tagged SEL-10.
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crossed with CB4856. Recombinants were analyzed for the
presence of n3717gf or n1077gf by scoring for the presence of
CEMs and for an Egl phenotype as described below, and SNPs
were genotyped by performing PCR and subsequent restriction
digests (19).
Isolation of sel-10 Deletion Mutants. Genomic DNA pools from
mutagenized animals were screened for deletions as described
(20). Deletion mutant animals were identified by nested PCR,
isolated from frozen stocks, and outcrossed at least three times.
Microscopic Analyses of Mutant and Transgenic Animals. The Egl
phenotype of sel-10 gf animals and the presence of HSNs were
analyzed as described (21). To score for the presence of CEMs,
we anesthetized L4 larvae with 50 mM sodium azide and
examined all four CEM positions by using Nomarski microscopy
(22). In SNP mapping and epistasis analysis with sel-10(n3717
gf), we scored the presence of CEMs by using the pkd-2::gfp
reporter nIs133. Hermaphrodite fertility was tested by picking
individual L4 hermaphrodites and, 72 h later, analyzing whether
progeny had been generated. Brood sizes were determined by
picking individual L4 hermaphrodites, transferring them to fresh
plates daily for 4 days, and counting all generated progeny. We
scored as males both animals that appeared fully male-like (most
of which were presumably pseudomales, defined as XX animals
that were essentially completely masculinized) and intersexes
with severely masculinized tails, as determined by using a
dissecting microscope (23).
Molecular Analysis. pBC262 contains a 6.9-kb XbaI fragment of
cosmid F55B12 (from base pairs 7,986 to 14,853; all references
to F55B12 sequence refer to GenBank accession no. Z79757)
ligated into Bluescript KS(). The sequences of mutant alleles
of sel-10 were determined from PCR-amplified genomic DNA.
The plasmids pQNClacZ, pQNCsel-10myc, and pQNCsel-10HA
(17, 24) were used for transient transfections. fem-1, fem-2, and
fem-3 cDNAs were amplified from plasmids AS1000, AS1245,
and AS1197 (6) to introduce a Flag-tag or Myc-tag. The tra-2
fragment encoding TRA-2C (25), was amplified from the plas-
mid pPK148. The PCR products were cloned into the expression
vector pcDNA.3 (Invitrogen). For construction of a plasmid
driving the expression of human sel-10 (hsel-10) short-hairpin
RNA (shRNA), we used appropriate oligonucleotides that were
annealed and ligated into the vector pSHAG-1 (26).
Transgenic Animals. Germline transformation was performed as
described (27). Cosmid DNA (5–8.5 gml each) was injected
into sel-10(n1077gf) unc-76(e911) animals with the unc-76 res-
cuing construct p76-16B (50 gml) (28).
Transfections, Immunoprecipitations, and Western Blot Analysis. For
coimmunoprecipitation experiments, U2OS cells were grown to
50% confluency in DMEM supplemented with 10% FBS and
transfected by using FuGENE 6 (Roche). We added a LacZ-
containing plasmid (pQNClacz) to keep the total amount of
DNA constant. At 24 h after transfection, cells were lysed in Flag
lysis buffer (50 mM TrisHCl, pH 7.8137 mM NaCl10 mM
NaF1 mM EDTA10% glycerin1% Triton X-1000.2% sar-
kosyl) and 1 complete protease inhibitor mixture (Roche). Cell
lysates were incubated with anti-Flag M2 affinity gel (Sigma) or
anti-Myc agarose (Santa Cruz Biotechnology) for 2 h at 4°C. The
beads were washed three times with Flag lysis buffer and boiled
in sample buffer. Precipitated proteins were analyzed by using
anti-Flag M2 antibodies (Sigma) and polyclonal anti-Myc anti-
bodies (Santa Cruz Biotechnology). For detection of protein
steady-state levels, the expression plasmids were transfected into
BOSC cells. A plasmid pSHAG-Ff1 expressing firefly luciferase
shRNA (26) was used as a negative control (control shRNA).
Cell cultures were treated for 8 h with the proteasome inhibitor
lactacystin (5M; Sigma). The FEM proteins were detected with
anti-Flag M2 antibodies.
Results
The egl-41 Mutation n1077 Causes Altered egl-41 Activity That Is
Antagonized by Wild-Type egl-41 Activity. egl-41(n1077) semidomi-
nantly causes a cold-sensitive Egl phenotype (see Table 8, which is
published as supporting information on the PNAS web site) (13).
egl-41 is not haploinsufficient for feminization because nDf42
hermaphrodites (nDf42 is a deficiency that deletes the egl-41 locus)
(14) were not Egl (see Table 9, which is published as supporting
information on the PNAS web site). The semidominant egl-41
phenotype is not likely to be caused by an increase in wild-type
egl-41 activity. Hermaphrodites carrying the duplication ctDp8,
which spans the egl-41 locus (; ctDp8) (18), were non-Egl
(Table 9), and 54% of n1077 hermaphrodites but only 24% of
n1077 hermaphrodites (n1077; ctDp8) were Egl (Table 9),
which also indicates that the semidominant activity of egl-41(n1077)
can be antagonized by wild-type activity. However, n1077 homozy-
gotes had a more penetrant Egl phenotype than n1077nDf42
heterozygotes (100% and 26% penetrant for Egl, respectively;
Tables 8 and 10, which are published as supporting information on
the PNAS web site), which indicates that n1077 does not simply
antagonize wild-type egl-41 activity and must cause altered gene
function. Therefore, we refer to the eight semidominantly acting
egl-41 alleles as gf mutations.
All Eight Independently Isolated egl-41 (gf) Mutants Carry an Identical
Mutation in the sel-10 ORF. We mapped egl-41(n3717gf) to a 130-kb
interval on linkage group V and found that the Egl phenotype
of and masculinization caused by egl-41(n1077gf) could be
suppressed by a 6.9-kb fragment of cosmid F55B12 (base pairs
7,986–14,853) (see Fig. 4A, which is published as supporting
information on the PNAS web site). This fragment contains the
previously characterized gene sel-10 and the 5 region of
F55B12.4, a gene encoding a poly(A) polymerase-like protein
(Fig. 4B).
sel-10, which encodes a 587-aa F-box protein, was previously
defined by the loss-of-function (lf) mutations ar28 and ar41 (17, 29).
sel-10 is a negative regulator of lin (lineage abnormal)-12 , which
encodes a Notch-like receptor. The SEL-10 protein can interact
with the intracellular domain of the LIN-12 protein in mammalian
cells (17), and mammalian SEL-10 interacts with the intracellular
domain of mammalian Notch, NIC, targeting it for ubiquitin-
mediated degradation (24, 30, 31). SEL-10 also appears to be a
negative regulator of the presenilin SEL-12, and mammalian
SEL-10 targets the presenilin PS1, which has been implicated in
Alzheimer’s disease, for degradation (32–34). SEL-10 contains
eight WD40 repeats, which are located in the C-terminal half of the
protein (17, 35). ar41 and ar28 are nonsense mutations that truncate
SEL-10 in WD40 repeats II and VII, respectively (17). We found
that all eight egl-41(gf) mutants have an identical mutation leading
to a glycine-to-glutamic acid substitution at position 567 in WD
repeat VIII (Fig. 4C).
egl-41 and sel-10 Are the Same Gene. To identify dominant suppres-
sors of the Egl phenotype of n1077gf animals, we mutagenized
homozygous n1077gf hermaphrodites and screened the F1 self-
progeny for rare, non-Egl hermaphrodites. From the 20,000 mu-
tagenized haploid genomes that were screened, we recovered one
mutation, bc189, that semidominantly suppressed the Egl pheno-
type and the masculinization caused by egl-41(n1077gf) (Tables
10–12, which are published as supporting information on the PNAS
web site). bc189 is tightly linked to egl-41 (data not shown) and is
an lf allele of sel-10: (i) like sel-10(ar41), bc189 is a modifier of lin-12
and a suppressor of sel-12 (ar131) (Tables 13–15, which are pub-
lished as supporting information on the PNAS web site); (ii) bc189
12550  www.pnas.orgcgidoi10.1073pnas.0405087101 Ja¨ger et al.
failed to complement sel-10(ar41) for suppression of sel-12(ar131)
(Table 15); and (iii) bc189 animals have a missense mutation in
sel-10, leading to an aspartic acid-to-asparagine substitution at
position 482 in WD40 repeat VI (Fig. 4C). We used a cis–trans test
to determine whether sel-10(bc189) is in the same gene as egl-
41(n1077gf). Specifically, we used bc189 as a sel-10 (lf) mutation in
cis to egl-41(n1077gf) (genotype bc189 n1077) and compared
bc189 n1077 animals with animals carrying the sel-10 (lf) mu-
tation ar41 in trans to egl-41(n1077gf) (genotype n1077ar41)
(Table 12). sel-10 (lf) in cis to n1077gf, but not in trans to n1077gf,
suppressed the Egl phenotype of n1077, indicating that the muta-
tions affect the same gene. Henceforth, we refer to egl-41 as sel-10.
sel-10(n1077gf) Shares Selected Characteristics with sel-10 (lf) Muta-
tions. sel-10(n1077gf) behaved similarly to the sel-10 (lf) muta-
tions ar41 and bc189 n1077 in elevating lin-12 function: it
suppressed the two-anchor-cell defect caused by the weak lin-12
lf allele lin-12(n676 n930) (29) and enhanced the Muv (multi-
vulva) phenotype caused by the weak lin-12 gf allele lin-12(n302)
(17) (Tables 13 and 14). Unlike sel-10 (lf), sel-10(n1077gf) did
not suppress the Sel-12-Egl phenotype caused by sel-12(ar131)
(29, 32, 36) (Table 15). These findings suggest that the sel-10 (gf)
mutation affects a sel-10 function that is involved in the regu-
lation of LIN-12 but not of SEL-12.
The sel-10 Null Phenotype Is a Weak Masculinization of Hermaphro-
dites. We isolated two deletion mutations in the sel-10 gene, bc243
and n4273, which delete 851 bp (10,103–10,953 of F55B12) and 956
bp (10,323–11,278 of F55B12) and are predicted to truncate SEL-10
after amino acids 85 and 106, respectively (Fig. 4 B and C). The
resulting proteins should lack the F-box and all eight WD40 repeats.
bc243 and n4273 most likely are null alleles of sel-10. Like sel-
10(ar41) and sel-10(bc189 n1077) animals, bc243 and n4273 her-
maphrodites appear grossly wild-type. We found that bc243 and
n4273 suppressed lin-12(n676 n930) and sel-12(ar131) and en-
hanced lin-12(n302gf) to a degree similar to that seen with sel-
10(ar41) (Tables 13–15 and data not shown). Thus, as proposed in
ref. 17, ar41 represents a null allele.
sel-10(n1077gf) enhances the Tra phenotype caused by weak
lf mutations of tra-2 (13). Therefore, we tested whether null
alleles of sel-10 could modify the Tra phenotypes caused by a gf
mutation of her-1 or by weak lf mutations of sdc (sex determi-
nation and dosage compensation)-1 (sdc-1 negatively regulates
her-1) or tra-2. By several criteria, we found that sel-10 (lf)
enhanced their Tra phenotypes (Tables 1–3). In addition, her-
maphrodites homozygous for any of the three sel-10 null muta-
tions exhibited defects indicative of weak masculinization, in-
cluding the absence of HSNs and the presence of CEMs
(Tables 2 and 3), albeit to a far lesser degree than seen for
sel-10(n1077gf) animals (Table 11). Thus, the sel-10 null phe-
notype with respect to sex determination is a weak masculin-
ization of hermaphrodites. We conclude that sel-10 promotes
hermaphrodite development.
sel-10 Acts Upstream of fem-1, fem-2, and fem-3 and Downstream of
her-1 and Possibly tra-2. To place sel-10 function within the sex-
determination pathway, we examined the interactions of sel-10 null
mutations with lf mutations in her-1, fem-1, fem-2, and fem-3. To
ensure detection of the weak masculinizing effects of sel-10 (lf), we
used temperature-sensitive, partial lf mutations of her-1, fem-1,
fem-2 and fem-3 under sensitized conditions that cause a partial
feminization of X0 animals. sel-10 (lf) could masculinize X0 animals
feminized by her-1(e1561) but not X0 animals feminized by fem-
1(hc17), fem-2(b245), or fem-3(e2006) (Tables 4 and 5). These
Table 1. sel-10 lf mutations enhance the ability of various tra
mutations to masculinize hermaphrodites
Genotype
% Tra animals (n)
 sel-10(ar41) sel-10(bc243) sel-10(n4273)
 0 (Many) 0 (Many) 0 (Many) 0 (Many)
sdc-1(n485) 10 (223) 52 (105) 76 (82) 73 (70)
her-1(n695gf) 28 (113) 89 (155) ND — ND —
tra-2(n1106) 8 (266) 32 (117) 25 (101) 29 (120)
tra-2(e1875) 1 (257) 3 (152) 3 (96) 8 (101)
The Tra phenotype was scored as described in Materials and Methods. The
complete genotypes of the analyzed animals were as listed, except that all
strains containing her-1(e695) were homozygous for dpy-11(e224) and all
strains containing sel-10(ar41) were homozygous for lon-3(e2175). ND, not
determined.
Table 2. sel-10 lf mutations enhance the ability of various tra
mutations to cause the HSNs to undergo programmed cell death
Genotype
% HSNs missing in hermaphrodites (n)
 sel-10(ar41) sel-10(bc243) sel-10(n4273)
 0 (Many) 2 (60) 7 (60) 9 (60)
sdc-1(n485) 34 (110) 76 (50) 78 (60) 77 (60)
her-1(n695gf) 90 (50) 92 (50) ND — ND —
tra-2(n1106) 85 (110) 86 (50) 87 (60) 83 (60)
tra-2(e1875) 32 (220) 81 (110) 60 (60) 60 (60)
The presence of HSNs was scored as described in Materials and Methods. The
genotypes of the animals were as described for Table 1. ND, not determined.
Table 3. sel-10 lf mutations enhance the ability of various tra
mutations to cause CEMs survival
Genotype
% CEMs present in hermaphrodites (n)
 sel-10(ar41) sel-10(bc243) sel-10(n4273)
 0 (Many) 2 (168) 4 (160) 7 (152)
sdc-1(n485) 21 (376) 46 (80) 35 (80) 39 (80)
her-1(n695gf) 80 (80) 85 (80) ND — ND —
tra-2(n1106) 84 (160) 91 (80) 84 (80) 83 (80)
tra-2(e1875) 44 (156) 65 (80) 69 (80) 68 (80)
The presence of CEMs was scored as described in Materials and Methods. The
genotypes of the animals were as described for Table 1. ND, not determined.
Table 4. sel-10(ar41) partially suppresses the feminization of X0
animals caused by her-1(e1561lf)
Genotype
% Males (n)
15°C 24.5°C
him-8(e1489) 30 (209) 34 (273)
him-8(e1489); her-1(e1561) 36 (270) 12 (217)
him-8(e1489); sel-10(ar41) 38 (252) 32 (93)
him-8(e1489); her-1(e1561) 34 (291) 30 (205)
sel-10(ar41)
him-8(e1489); sel-10(bc243) 40 (181) 42 (186)
him-8(e1489); her-1(e1561) 41 (207) 30 (186)
sel-10(bc243)
him-8(e1489); sel-10(n4273) 37 (194) 35 (221)
him-8(e1489); her-1(e1561) 36 (114) 24 (256)
sel-10(n4273)
“Males” were identified based on the criteria described in Materials and
Methods. The complete genotypes of the animals analyzed were as listed,
except for the second through fourth strains, as listed from top to bottom,
which were as follows: him-8(e1489); her-1(e1561) unc-76(e911), him-
8(e1489); lon-3(e2175) sel-10(ar41), and him-8(e1489); her-1(e1561) lon-
3(e2175) sel-10(ar41) unc-76(e911).
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results suggest that sel-10 functions downstream of or in parallel to
her-1 and upstream of or in parallel to fem-1, fem-2, and fem-3.
Furthermore, sel-10 (lf) partially suppressed the Fem phenotypes
caused by the dominantly acting ‘‘enhanced gf’’ mutation e2531 (11)
and the ‘‘mixed character’’ mutations e2019 and e2021 (37) of tra-2
(Tables 6 and 7). These findings suggest that sel-10 acts downstream
of or in parallel to tra-2. Results similar to those obtained with sel-10
(lf) were obtained for the stronger masculinizing effect of the sel-10
(gf) mutation: it has been reported that the Egl phenotype of
sel-10(e2055gf) hermaphrodites is suppressed by a null mutation in
fem-1 (14), and we found that CEM survival caused by
sel-10(n3717gf) was suppressed by null mutations in any of the three
fem genes but was not suppressed by a null mutation in her-1 (data
not shown).
SEL-10 Interacts Physically with the FEM Proteins. F-box proteins,
which were first described as exchangeable subunits of the
Skp1–Cullin–F-box (SCF) E3 ubiquitin-protein ligase complex,
interact with the Skp1 subunit of the complex via their F-box
domains (38, 39). Many F-box proteins contain protein–protein
interaction domains, such as leucine-rich domains or WD40
repeats that recruit protein substrates for ubiquitination (38, 39).
Our epistasis studies suggest that the fem genes are negatively
regulated by sel-10. Therefore, we tested whether the FEM
proteins interact with SEL-10 by performing coimmunoprecipi-
tation experiments using U2OS human osteosarcoma cells tran-
siently transfected to express Flag-tagged FEM-1, FEM-2, or
FEM-3; Myc-tagged SEL-10 (SEL-10Myc); or both a Flag-
tagged FEM protein and SEL-10Myc (Fig. 1). We immunopre-
cipitated the Flag-tagged proteins and detected SEL-10Myc only
in the precipitates from lysates expressing both SEL-10Myc and
any Flag-tagged FEM protein. Similarly, the immunoprecipita-
tion of SEL-10Myc resulted in the detection of Flag-tagged FEM
proteins only in the precipitates of cell lysates expressing both
SEL-10Myc and any Flag-tagged FEM protein (Fig. 1). Flag-
tagged TRA-2C did not precipitate SEL-10Myc (Fig. 1). Thus,
when expressed in mammalian cells, SEL-10 can physically
interact with each of the three C. elegans FEM proteins either
directly or through other proteins.
The Levels of FEM-1 and FEM-3 Are Regulated by SEL-10 and the
Proteasome. The ability of SEL-10 to interact with the FEM
proteins suggested that SEL-10 might target the FEM proteins for
proteasomal destruction. The coexpression of SEL-10Myc and
Flag-tagged FEM-1 in BOSC human embryonic kidney cells did
not result in decreased FEM-1 protein levels (data not shown).
However, FEM-1 protein levels were increased in the presence of
Fig. 1. The FEM proteins interact with SEL-10 in mammalian cells. Extracts
from mammalian U2OS cells expressing SEL-10Myc; Flag-tagged FEM-1, -2, or
-3; Flag-tagged TRA-2C; or both SEL-10Myc and the indicated Flag-tagged
protein were immunoprecipitated by anti-Flag M2 or anti-Myc antibodies. The
precipitated proteins were analyzed for the presence of SEL-10Myc with
anti-Myc antibodies and the Flag-tagged proteins with anti-Flag M2 antibodies.
Table 5. sel-10(ar41) fails to suppress the feminization of X0
animals caused by lf mutations in fem-1, fem-2, and fem-3
Genotype
% CEMs in X0 (n)
 sel-10(ar41)
* 91 (80) 91 (100)
fem-1(hc17)* 51 (100) 53 (112)
fem-2(b245)* 73 (100) 75 (220)
† 91 (80) 89 (156)
fem-3(e2006)† 55 (176) 55 (92)
The presence of CEMs in X0 animals was scored as described in Materials
and Methods. The complete genotypes of the animals analyzed were as listed
save that all strains contain him-1(e879) and all strains containing sel-10(ar41)
are homozygous for lon-3(e2175).
*Animals were cultured at 25°C until reaching the second larval stage, and
then the temperature was shifted to 16°C.
†Animals were cultured at 20°C.
Table 6. sel-10(ar41) partially suppresses the feminization of X0
animals caused by tra-2(e2531eg)
Genotype % CEMs present in X0 (n)
sel-10(ar41) 91 (100)
tra-2(e2531eg) 15 (120)
tra-2(e2531eg); sel-10(ar41) 40 (172)
The presence of CEMs in X0 animals was scored as described in Materials
and Methods. The complete genotypes of the analyzed animals were, from
top to bottom, as follows: him-1(e879); lon-3(e2175) sel-10(ar41), tra-
2(e2531), tra-2(e2531); lon-3(e2175) sel-10(ar41). eg, Enhanced gf.
Table 7. sel-10(ar41) partially suppresses the germline
feminization in XX animals caused by tra-2 (mx) mutations
Genotype
% Fertile
animals (n)
Average no.
of progeny Range n
sel-10(ar41) 100 (58) 277 243–328 6
tra-2(e2019mx) 10 (102) 70 18–104 6
tra-2(e2019mx); sel-10(ar41) 22 (102) 127 20–180 6
tra-2(e2021mx) 13 (101) 60 7–108 7
tra-2(e2021mx); sel-10(ar41) 46 (101) 129 34–210 6
The number of fertile animals and the number of progeny were analyzed
as described in Materials and Methods. The complete genotypes of the
animals analyzed were as listed except that all strains containing sel-10(ar41)
were homozygous for lon-3(e2175). mx, Mixed character.
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lactacystin, a proteasome inhibitor (Fig. 2). We postulated that
transfected FEM-1 might be targeted by hSEL-10 (FBW7), which
is 46% identical to C. elegans SEL-10. To reduce the amount of
endogenous hSEL-10, we generated specific shRNA (26) against
the hsel-10 gene. We transiently transfected BOSC cells to express
Flag-tagged FEM-1 and either control firefly luciferase shRNA or
hsel-10 shRNA. When compared with control cells, the steady-state
level of FEM-1 was increased in the hsel-10 shRNA cells to a level
similar to the level of FEM-1 found in cells treated with lactacystin
(Fig. 2). In analogous experiments, lactacystin and hsel-10 shRNA
increased the protein level of FEM-3 but did not affect the protein
level of FEM-2 (Fig. 2). Together, these results indicate that the
steady-state levels of transfected FEM-1 and FEM-3 in BOSC cells
depend on the presence of hSEL-10 and a functional proteasome.
Discussion
Our genetic analysis indicates that egl-41 mutations cause mas-
culinization as a result of altered function of sel-10 and further
demonstrates that sel-10 wild-type function is required for
normal hermaphrodite development. That null mutations of
sel-10 cause a weak phenotype might be explained by the fact that
the genome of C. elegans is predicted to encode at least 326 F-box
proteins (40). Hence, sel-10 might be functionally redundant with
other, similar proteins. Alternately, the sex determination pro-
cesses in which sel-10 is involved, for example the degradation of
FEM-1 and FEM-3, might be redundant (i.e., pathways other
than a proteasome-dependent pathway might negatively regulate
the activities of the fem genes).
The sel-10 (gf) mutation results in the alteration of a con-
served residue in WD40 repeat VIII. We propose that rather
than decreasing binding to substrate or the SCF complex, this
mutation might result in the formation of stable but nonfunc-
tional SCFSEL-10(gf) complexes. By causing the formation of such
complexes, SEL-10 (gf) protein could prevent wild-type SEL-10
protein as well as additional functionally redundant F-box pro-
teins from entering SCF complexes and from mediating the
ubiquitination and degradation of their substrates. This model
could explain why different processes are affected to differing
degrees by the sel-10 (gf) mutation and the sel-10 (lf) mutations.
SEL-10 might be the sole or principal F-box protein responsible
for regulating lin-12 activity, which is affected similarly by sel-10
gf and lf mutations. By contrast, in sex determination, F-box
Fig. 2. FEM-1 and FEM-3 may be targeted by hSEL-10 for degradation by the
proteasome. To analyze protein steady-state levels, we treated BOSC cells
expressing Flag-tagged FEM-1, -2 or -3, respectively, with lactacystin to inhibit
the proteasome or with hsel-10 shRNA to partially inactivate hsel-10. The
untreated and lactacystin-treated cells were cotransfected with a plasmid
expressing control shRNA (firefly luciferase). Whole-cell lysates were analyzed
by using anti-Flag M2 antibodies. Representative data from three indepen-
dent experiments are shown.
Fig. 3. Genetic and molecular pathways of somatic sex determination in C. elegans. (A) A simplified genetic pathway for sex determination in the C. elegans
soma is shown. sel-10 is a new gene in this pathway and acts as a negative regulator of the fem genes. (B) A model for the molecular interactions among SEL-10,
the FEM proteins, TRA-1, and TRA-2. SEL-10 negatively regulates FEM-1 and FEM-3 by promoting the degradation of their phosphorylated forms. A negative
arrow from TRA-2 to FEM-3 reflects the possibility that TRA-2 directly binds and inhibits FEM-3 (7). See text for details.
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proteins in addition to SEL-10 might mediate the degradation of
FEM-1 and FEM-3. In sel-10 (lf) animals, these redundant F-box
proteins could largely substitute for SEL-10 function in FEM-1
and FEM-3 degradation, resulting in a weak defect in sex
determination; in sel-10 (gf) animals, nonfunctional SCFSEL-10(gf)
complexes would prevent redundant F-box proteins from sub-
stituting for SEL-10 function, leading to a stronger defect.
The finding that sel-12 (lf) is not suppressed by the sel-10 (gf)
mutation indicates that SCFSEL-10(gf) complexes might still be
functional with respect to sel-12 function. The interaction be-
tween SEL-10 and SEL-12, therefore, might differ from other
SEL-10-substrate interactions, a difference that may be evolu-
tionarily conserved in the interaction of the homologous proteins
hSEL-10 and PS1 in Alzheimer’s disease (32–34).
Genetically, sel-10 wild-type function is likely to act downstream
of or in parallel to tra-2 as a negative regulator of fem-1, fem-2, and
fem-3 (Fig. 3A). When expressed in mammalian cells, SEL-10
interacted with FEM-1, FEM-2, and FEM-3, and hSEL-10 medi-
ated the degradation of FEM-1 and FEM-3 by the proteasome. We
propose that sel-10 promotes female development by down-
regulating fem-1 and fem-3 activities, which are required for male
development. It has been proposed that fem-1 and fem-3 are
regulated posttranscriptionally (3, 41–43). In the germline of XX
animals fem-3 activity is down-regulated at the level of translation
(44). Mutations that disrupt this regulation masculinize the XX
germline but do not detectably affect the sexual fate of the XX soma
(45). Thus, a different or an additional mechanism must be invoked
in the soma. Our data suggest that, in the soma, fem-1 and fem-3
activities are regulated at least in part at the level of protein stability
by means of a SEL-10-mediated process.
The direct or indirect target of the FEM proteins is the
transcription factor TRA-1. One mechanism that controls
TRA-1 activity seems to be the regulation of TRA-1 localization.
TRA-1 is preferentially exported from the nucleus in males or
masculinized XX animals, a process that requires a functional
fem-1 gene (46). Therefore, it has been proposed that the FEM
proteins might act to promote the export of TRA-1 from the
nucleus (47). Mammalian SEL-10 has been shown to localize to
and function in the nucleus (30, 31). It is possible that in XX
animals SEL-10 binds to nuclearly localized FEM-1 and FEM-3
proteins and mediates their degradation, thereby preventing
FEM protein-mediated export of TRA-1 and allowing TRA-1 to
remain inside the nucleus and promote female development. A
model in which SEL-10 mediates the degradation specifically of
nuclearly localized FEM-1 and FEM-3 could also explain the
finding that the overall level of FEM-1 protein appears to be
similar in XX and X0 animals (41). In X0 animals, by contrast,
SEL-10 would be prevented from binding FEM-1 and FEM-3
protein, resulting in the FEM-dependent export of TRA-1 out of
the nucleus and subsequent male development (Fig. 3B).
A prerequisite for substrate recognition by the SCF complex
seems to be substrate phosphorylation (39). SCFSEL-10-mediated
degradation of FEM-1 and FEM-3 might, therefore, depend on
their phosphorylation. The type 2C protein phosphatase FEM-2
acts at the same step of the sex-determination pathway, and its
phosphatase activity is required for male development (4, 5).
FEM-2 can interact with FEM-3 (5) and also with FEM-1 (48).
Therefore, we suggest that in XX animals, FEM-1 and FEM-3
are phosphorylated by an unidentified protein kinase and that
this phosphorylation is promoted by TRA-2 in XX animals and
antagonized by FEM-2 in X0 animals (Fig. 3B).
We thank Heinke Schnabel, Simon Tuck, Craig Ceol, and Erik Andersen
for comments about the manuscript; Iva Greenwald, Jonathan Hodgkin,
Patty Kuwabara, Tim Schedl, and Jochen Strayle for discussions; Bren-
dan Galvin for the sel-10 alleles n3854, n4041, and n4046; Jonathan
Hodgkin, Patty Kuwabara, and Iva Greenwald for other strains; Andrew
Spence for plasmids AS1000, AS1197, and AS1245; Patty Kuwabara for
plasmid pPK148; Jan Kitajewski for plasmids pQNClacZ, pQNCsel-
10myc, and pQNCsel-10HA; and Greg Hannon for plasmids pSHAG-1
and pSHAG-Ff1. We also thank Alan Coulson and the Sanger Centre
(Hinxton, U.K.) for cosmids and the C. elegans Genetics Center (CGC,
supported by the National Institutes of Health National Center for
Research Resources) for strains; Claudia Huber and Andrew Hellman
for technical support; and Helma Tyrlas and Beth Castor for DNA
sequence determinations. This work was supported by United States
Public Health Service Research Grant GM24663 (to H.R.H.) and by the
Max Planck Society, a European Molecular Biology Organization Young
Investigator Award, and Howard Hughes Medical Institute Award
76200-560801 to Dartmouth Medical School under the Biomedical
Research Support Program for Medical Schools (to B.C.). H.T.S. was
supported by a David H. Koch Graduate Fellowship. H.R.H. is the David
H. Koch Professor of Biology at Massachusetts Institute of Technology
and an Investigator of the Howard Hughes Medical Institute.
1. Madl, J. E. & Herman, R. K. (1979) Genetics 93, 393–402.
2. Perry, M. D., Li, W., Trent, C., Robertson, B., Fire, A., Hageman, J. M. & Wood,
W. B. (1993) Genes Dev. 7, 216–228.
3. Ahringer, J., Rosenquist, T. A., Lawson, D. N. & Kimble, J. (1992) EMBO J. 11, 2303–2310.
4. Pilgrim, D., McGregor, A., Jackle, P., Johnson, T. & Hansen, D. (1995) Mol. Biol. Cell
6, 1159–1171.
5. Chin-Sang, I. D. & Spence, A. M. (1996) Genes Dev. 10, 2314–2325.
6. Spence, A. M., Coulson, A. & Hodgkin, J. (1990) Cell 60, 981–990.
7. Mehra, A., Gaudet, J., Heck, L., Kuwabara, P. E. & Spence, A. M. (1999) Genes Dev.
13, 1453–1463.
8. Zarkower, D. & Hodgkin, J. (1992) Cell 70, 237–249.
9. Conradt, B. & Horvitz, H. R. (1999) Cell 98, 317–327.
10. Yi, W., Ross, J. M. & Zarkower, D. (2000) Development 127, 4469–4480.
11. Kuwabara, P. E. (1996) Development (Cambridge, U.K.) 122, 2089–2098.
12. Sokol, S. B. & Kuwabara, P. E. (2000) Genes Dev. 14, 901–906.
13. Desai, C. & Horvitz, H. R. (1989) Genetics 121, 703–721.
14. Doniach, T. (1986) Genetics 114, 53–76.
15. Riddle, D. L., Blumenthal, T., Meyer, B. J. & Priess, J. R. (1997) C. elegans II (Cold
Spring Harbor Lab. Press, Plainview, New York).
16. Barr, M. M. & Sternberg, P. W. (1999) Nature 401, 386–389.
17. Hubbard, E. J., Wu, G., Kitajewski, J. & Greenwald, I. (1997) Genes Dev. 11,
3182–3193.
18. Hunter, C. P. & Wood, W. B. (1992) Nature 355, 551–555.
19. The C. elegans Sequencing Consortium (1998) Science 282, 2012–2018.
20. Jansen, G., Hazendonk, E., Thijssen, K. L. & Plasterk, R. H. (1997) Nat. Genet. 17,
119–121.
21. Conradt, B. & Horvitz, H. R. (1998) Cell 93, 519–529.
22. Sulston, J. E., Schierenberg, E., White, J. G. & Thomson, J. N. (1983) Dev. Biol. 100,
64–119.
23. Hodgkin, J. (1987) Genes Dev. 1, 731–745.
24. Wu, G., Lyapina, S., Das, I., Li, J., Gurney, M., Pauley, A., Chui, I., Deshaies, R. J.
& Kitajewski, J. (2001) Mol. Cell. Biol. 21, 7403–7415.
25. Lum, D. H., Kuwabara, P. E., Zarkower, D. & Spence, A. M. (2000) Genes Dev. 14,
3153–3165.
26. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. & Conklin, D. S. (2002)
Genes Dev. 16, 948–958.
27. Mello, C. & Fire, A. (1995) Methods Cell Biol. 48, 451–482.
28. Bloom, L. & Horvitz, H. R. (1997) Proc. Natl. Acad. Sci. USA 94, 3414–3419.
29. Sundaram, M. & Greenwald, I. (1993) Genetics 135, 765–783.
30. Gupta-Rossi, N., Le Bail, O., Gonen, H., Brou, C., Logeat, F., Six, E., Ciechanover,
A. & Israel, A. (2001) J. Biol. Chem. 276, 34371–34378.
31. Oberg, C., Li, J., Pauley, A., Wolf, E., Gurney, M. & Lendahl, U. (2001) J. Biol. Chem.
276, 35847–35853.
32. Levitan, D. & Greenwald, I. (1995) Nature 377, 351–354.
33. Wu, G., Hubbard, E. J., Kitajewski, J. K. & Greenwald, I. (1998) Proc. Natl. Acad.
Sci. USA 95, 15787–15791.
34. Li, J., Pauley, A. M., Myers, R. L., Shuang, R., Brashler, J. R., Yan, R., Buhl, A. E.,
Ruble, C. & Gurney, M. E. (2002) J. Neurochem. 82, 1540–1548.
35. Orlicky, S., Tang, X., Willems, A., Tyers, M. & Sicheri, F. (2003) Cell 112, 243–256.
36. Li, X. & Greenwald, I. (1997) Proc. Natl. Acad. Sci. USA 94, 12204–12209.
37. Kuwabara, P. E., Okkema, P. G. & Kimble, J. (1998) Dev. Biol. 204, 251–262.
38. Patton, E. E., Willems, A. R. & Tyers, M. (1998) Trends Genet. 14, 236–243.
39. Deshaies, R. J. (1999) Annu. Rev. Cell Dev. Biol. 15, 435–467.
40. Kipreos, E. T. & Pagano, M. (2000) Genome Biol. 1, 3002.1–3002.7.
41. Gaudet, J., VanderElst, I. & Spence, A. M. (1996) Mol. Biol. Cell 7, 1107–1121.
42. Doniach, T. & Hodgkin, J. (1984) Dev. Biol. 106, 223–235.
43. Hodgkin, J. (1986) Genetics 114, 15–52.
44. Ahringer, J. & Kimble, J. (1991) Nature 349, 346–348.
45. Barton, M. K., Schedl, T. B. & Kimble, J. (1987) Genetics 115, 107–119.
46. Segal, S. P., Graves, L. E., Verheyden, J. & Goodwin, E. B. (2001) Dev. Cell 1, 539–551.
47. Goodwin, E. B. & Ellis, R. E. (2002) Curr. Biol. 12, R111–R120.
48. Tan, K. M. L., Chan, S.-L., Tan, K. O. & Yu, V. C. (2001) J. Biol. Chem. 276,
44193–44202.
12554  www.pnas.orgcgidoi10.1073pnas.0405087101 Ja¨ger et al.
